Skip to main content

Advertisement

Table 3 In vitro anticancer screening of the synthesized compounds against human breast carcinoma cell line (MCF-7)

From: Design, synthesis, and biological evaluation of novel N4-substituted sulfonamides: acetamides derivatives as dihydrofolate reductase (DHFR) inhibitors

Comp. no. Validity for sample conc. IC50 (μg mL−1)a IC50 (μM)a
500 250 125 62.50 31.25 15.60 7.80 3.90 2 1 0
5a 7.34 14.03 29.47 41.58 54.29 71.43 87.50 96.75 100 100 100 41.80 111.92
5b 7.13 13.42 30.96 42.37 56.29 68.41 83.77 91.40 98.32 100 100 45.40 112.52
5c 5.28 11.32 20.79 32.65 48.51 70.38 86.42 94.03 99.71 100 100 30.10 77.68
5d 3.46 7.28 15.09 27.41 36.27 45.62 63.18 80.94 93.46 99.53 100 13.70 33.59
5e 4.02 9.56 18.48 29.67 40.82 54.61 73.28 91.42 98.70 100 100 20.80 45.98
5f 6.17 14.38 27.56 39.4 53.29 68.43 81.70 93.68 99.85 100 100 38.70 86.86
5g 3.86 8.24 15.37 24.16 32.95 41.68 49.80 67.48 85.26 93.84 100 7.76 18.59
5h 3.94 7.81 16.23 31.42 39.79 48.20 67.41 82.76 91.30 98.72 100 14.90 35.61
5i 6.28 13.47 25.13 36.78 48.50 67.41 81.67 89.43 98.16 100 100 30.00 79.91
5j 4.17 9.82 18.78 27.05 35.23 46.19 54.82 69.46 87.34 94.29 100 12.10 29.84
5k 13.49 21.86 32.75 46.23 57.18 76.94 88.60 97.41 100 100 100 51.70 132.74
5l 2.73 6.46 11.38 24.95 34.89 42.67 51.53 65.76 83.20 91.42 100 9.140 22.30
5m 9.85 18.2 30.67 42.96 51.78 68.92 84.68 95.41 99.62 100 100 37.50 82.54
5n 7.63 15.26 27.39 38.04 46.15 58.20 71.36 88.42 96.28 100 100 26.20 58.55
5o 3.46 9.82 20.31 29.57 43.60 56.89 70.42 83.97 92.40 97.36 100 23.60 56.26
5p 4.98 11.75 21.42 36.75 50.38 69.41 85.26 93.02 99.76 100 100 32.10 76.35
6a 4.94 10.73 23.4 32.79 45.17 56.24 71.38 85.02 92.47 98.25 100 24.40 65.33
6b 8.71 20.42 37.53 49.81 62.97 85.46 93.04 99.32 100 100 100 62.00 153.66
6c 5.31 9.14 19.56 32.71 49.82 70.38 81.6 92.88 98.76 100 100 31.10 80.26
6d 6.79 13.4 19.85 27.93 36.7 48.61 63.87 76.45 88.29 96.36 100 14.90 36.53
6e 7.46 19.53 28.65 40.37 52.91 69.42 82.36 91.73 98.6 100 100 38.50 85.11
6f 9.56 17.28 28.67 36.7 50.98 67.39 82.15 93.69 98.72 100 100 33.40 74.97
6g 15.68 27.83 38.17 52.46 69.9 83.51 92.78 99.52 100 100 100 73.30 175.58
6h 2.37 7.54 15.18 23.65 34.89 45.13 60.97 75.86 87.41 95.64 100 13.20 31.54
6i 11.76 21.49 34.85 43.96 58.28 77.39 91.47 97.92 100 100 100 49.30 131.31
6j 5.92 11.48 23.69 34.73 47.21 68.46 80.93 92.64 98.23 100 100 29.14 71.87
6k 12.41 20.53 30.78 39.62 56.34 71.48 86.24 98.4 100 100 100 43.00 110.41
6l 10.32 19.67 32.94 41.78 51.85 65.04 79.12 90.65 97.54 100 100 36.90 90.02
6m 7.64 16.29 24.31 35.17 45.04 56.28 69.46 82.78 94.13 99.2 100 24.30 53.48
6n 19.47 31.85 40.91 49.76 58.49 71.32 86.95 97.81 100 100 100 61.60 137.65
6o 37.04 52.31 76.45 91.32 98.74 100 100 100 100 100 100 287.00 684.23
6p 3.45 9.74 20.37 31.96 46.29 70.34 85.21 93.18 99.4 100 100 28.70 68.26
5-FU 9.18 17.84 28.01 35.39 47.13 60.35 71.82 86.97 95.23 98.12 100 27.80 213.71
  1. IC50 value: concentration causing 50% inhibition of cell viability
  2. aMean of three results obtained from three experiments